Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2015

View Archived Issues

Pfizer synthesizes new Abeta production inhibitors

Selective Nav1.7 inhibitors for the treatment of pain

IncellDx and Claremont to combine technologies for liquid-based biopsy system

JCR Pharma initiates development of ERT using BBB-crossing technology

Nanosyn and LLS update progress of MLL leukemia project

Piramal Enterprises presents BRD4 inhibitors

Sunshine Lake Pharma presents SGLT2 inhibitors

GDF15 may be a superior biomarker for mitochondrial disease diagnosis

Johnson & Johnson recaps highlights of first quarter 2015

Ombitasvir/paritaprevir/ritonavir HCV combination granted priority review in Japan

Avelas starts phase I trial of real-time fluorescent illuminator for breast cancer surgery

Baxter files for approval of BAX-855 in Japan

Isarna Therapeutics initiates first-in-human trial of ISTH-0036

Receptos's ozanimod achieves efficacy endpoints in phase II ulcerative colitis trial

TC-6499 fails to reduce gastric emptying time in diabetic gastroparesis study

Tipelukast receives FDA fast track designation for NASH with fibrosis

Actelion updates on clinical development of S1P1 receptor modulators

Discovery Laboratories advances development of Aerosurf, ceases commercialization of Surfaxin

World Hemophilia Day: Hyperfunctional FIX as a promising tool in hemophilia

Anacor reports boron-containing PDE4 inhibitors

Merck & Co. develops Trk-A inhibitors

FDA grants orphan drug designation to selumetinib for uveal melanoma

Chugai presents anti-protein-C MAbs

Provectus initiates phase III trial of PV-10 in melanoma

Genmab achieves fifth milestone in daratumumab collaboration with Janssen Biotech

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...